Analyst consensus

As at 12 May 2023

FY23

 

Low

High

Average (Mean)

Revenue (£m)

1,267.0

1,347.7

1,295.0

EBITDA (£m)

223.7

240.6

231.5

EBIT (£m)

121.0

138.5

128.3

PBT (£m)

25.5

42.7

33.4

Net income (£m)

16.6

27.8

21.5

Adjusted EPS (p)

4.0

6.9

5.6

Net bank debt (£m)

(251.5)

(211.0)

(230.2)

Net debt (including lease liabilities) (£m)

(1,115.0)

(1,090.6)

(1,102.2)

FY24

 

Low

High

Average (Mean)

Revenue (£m)

1,322.2

1,428.3

1,371.6

EBITDA (£m)

249.3

265.3

258.2

EBIT (£m)

135.0

158.8

149.5

PBT (£m)

41.0

63.1

54.3

Net income (£m)

27.8

47.3

38.4

Adjusted EPS (p)

8.0

11.8

9.9

Net bank debt (£m)

(240.3)

(157.0)

(198.2)

Net debt (including lease liabilities) (£m)

(1,098.0)

(1,061.4)

(1,074.5)

 

The figures shown above are on an adjusted, post IFRS 16 basis. They include estimates from eight analysts at the following institutions who have updated their estimates in line with Company guidance following Spire Healthcare’s FY22 results: Barclays, Berenberg, JPM, Jefferies, Liberum, Numis, Peel Hunt and RBC.